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Abstract 
Very few in vivo animal studies involving vanadium consider 
the contribution of decavanadate (V10) to vanadium 
biological effects. Recently, it is been suggested that 
decameric vanadate may not completely fall apart into other 
vanadate oligomers before induces changes in cell 
homeostasis, namely in several stress markers. An acute 
exposure of different fish species (Halobactrachus didactilus, 
Lusitanian toadfish, and Sparus aurata, gilthead seabream) 
to decavanadate, but not to other vanadate oligomers, 
induced different effects than vanadate in catalase activity, 
glutathione content, lipid peroxidation, mitochondrial 
superoxide anion production and vanadium accumulation, 
whereas both solutions seem to equally depress reactive 
oxygen species (ROS) production as well as total 
intracellular reducing power. Vanadium is accumulated in 
Sparus aurata mitochondria in particular when decavanadate 
is administrated. Moreover, exposure to different vanadate 
oligomers induced morphological changes in fish cardiac, 
hepatic and renal tissues causing tissues lesions in the liver 
and kidney, but not cardiac tissue. Nevertheless, the results 
highlight that different vanadate oligomers seem to follow, 
not only in vitro but also in vivo, different pathways, with 
different targets and effects. These recent findings, that are 
now summarized, point out the decameric vanadate species 
contributions to in vivo effects induced by vanadium in 
biological systems. 
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1. INTRODUCTION 
 
Vanadium is a heavy metal with increased environmental circulation, resulting from 
various anthropogenic activities [1-3] and it is of great concern due to its toxicity and 
accumulative behaviour at specific target organs, such as the liver and kidney, inducing 
oxidative damage, lipid peroxidation and changes in haematological, reproductive and 
respiratory systems [4-9]. The formation of ROS induced by vanadium in biological 
systems may involve Fenton-like reactions [7], vanadate bioreduction mediated by reduced 
glutathione (GSH), flavoenzymes or nicotinamide adenine dinucleotide, reduced form 
(NADH), and nicotinamide adenine dinucleotide phosphate, reduced form (NADPH), 
oxidases [10-12] or interaction with mitochondria [13].  
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Vanadate oligomers are often not taken in account in most biological studies, in 
spite that at the concentrations normally used the vanadate solutions also contains several 
vanadate oligomers besides the monomeric vanadate (V1), such as dimeric (V2) and 
tetrameric (V4) vanadate species. Furthermore, it is recognized that the individual species 
may differently influence enzyme activities [14-19]. Decameric vanadate species (V10), for 
instance, are well known to affect the activity of several enzymes [18-20]. The probably 
reason why in vivo toxicological studies of vanadate oligomers effects are scarce is that, it 
is considered that almost 98% of vanadium in cells is present as vanadyl (+4 oxidation 
state), being the intracellular concentration of vanadium (+5, vanadate) very low to 
vanadate oligomers be formed. However, it has been proposed that once formed the rate of 
decavanadate decomposition is slow (half-life time of hours) enough to allow to study its 
effects not only in vitro, but also in vivo [15-16, 21-28]. More recently, it was described 
that decameric vanadate can be stabilized upon interaction with cytoskeleton and 
membrane proteins [29]. It is believed that, due to its stability at physiologic conditions, 
decavanadate is not completely disintegrated into other vanadate oligomers before induces 
changes in several stress markers [24].  
The pioneer studies on the interaction between decavanadate and proteins were 
performed with ribonucleases, in 1973 [30]. These and other studies demonstrated the 
decavanadate species as potentially responsible for the effects promoted in enzyme 
activities [14]. Since that, one thing is becoming clear, decavanadate seems to follow, not 
only in vitro but also in vivo, different pathways, with different targets and effects than 
other vanadate oligomers. The intracellular form of vanadium depends on the ratio of the 
whole pool of reductans to cell oxidants [31]. It is well known that, in the cell, vanadate is 
reduced to vanadyl, preventing the toxic effects of vanadium. However, vanadate reduction 
may not occur if the vanadate oligomers are present. Decameric species may eventually 
occur upon muscle cells acidification, becoming accessible to specific protein binding sites 
and inaccessible to reduction, thus inducing different cellular responses that the other 
vanadate species (Fig. 1). Therefore, a role of decameric vanadate species in the 
toxicological effects of vanadate in biological systems may be suggested.  
 
 
 
 
 
Figure 1. Scheme of the proposed cellular 
targets of decavanadate (V10): it is suggested V10 
uptake through anionic channels (AC) and/or V10 
binding to membrane proteins, as well as, V10 
formation upon intracellular acidification; it is 
also indicated the reduction of monomeric 
vanadate (V1) by antioxidant agents and the 
reduction of V10 by enzymes, as well as, the 
binding of V10 to target proteins preventing its 
reduction; and finally it is proposed the 
accumulation of V10 into subcellular organelles, 
such as mitochondria (adapted from Aureliano 
and Gândara [24]). 
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It is becoming apparent the interest and usefulness of piscine models to oxidative 
stress studies [32], which are more exposed to environmental pollutants. In fact, several 
works have reported that some fish species are far more sensitive to heavy metals toxic 
effects than mammals. Fish species, which has been used as preferential experimental 
models in toxicology studies, are very easy to obtain, maintain and to handle. Therefore, 
and besides the interest of piscine models to oxidative stress studies, our knowledge show 
us to be very useful to study decavanadate toxicity in fish species, since at the fish 
physiological temperature decameric vanadate species is stable enough to induce different 
effects than vanadate itself. 
Since 1999, our research group has performed in vivo administration of 
decavanadate in order to understand the contribution of decameric vanadate species to the 
toxic effects of vanadate [21-27]. Among the different experimental conditions, it was 
included different: (i) mode of decavanadate administration (intraperitoneal, i.p. versus 
intravenous, i.v.); (ii) fish species (Halobatrachus didactylus – Lusitanian toadfish – and 
Sparus aurata – gilthead seabream); (iii) vanadate concentration (1 and 5 mM); (iv) tissues 
(cardiac, hepatic, renal, blood); (v) subcellular fractions (cytosol, mitochondria, red blood 
cells, blood plasma); and (vi) exposure time (1, 6, 12, 24 hours, 2 and 7 days). A 
metavanadate solution, not containing decameric vanadate species, was always 
administered as a comparison group of study and, until now, following in vivo 
administration of decavanadate, several parameters were analysed such us: (i) vanadium 
subcellular distribution [21, 25-27]; (ii) histological changes on cardiac, hepatic and renal 
tissues [22]; (iii) effects on sarcoplasmic reticulum Ca2+-pump; (iv) lipid peroxidation; and 
(v) antioxidants enzymes activities besides several oxidative stress markers in heart [21, 24, 
27] and liver [24-25]. These previous reports indicated a different in vivo metabolic pattern 
for decameric vanadate species, pointing out the importance of vanadate speciation on the 
evaluation of vanadium toxicity in biology. Recently reported studies demonstrated that in 
vivo administration of different vanadate species induce different effects on vanadium 
subcellular distribution, tissue damage in liver, kidney and heart, lipid peroxidation and 
antioxidant enzymes [21-27].  
Therefore, it cannot be excluded the hypothesis that decavanadate once formed at 
physiological conditions, it may live for long enough to induce different biological effects 
than the ones observed for vanadate alone. The role of decameric vanadate in biological 
systems is still to be clarified and to our knowledge, in vivo toxicological studies of these 
species are scarce. In this sense, in the present report it is presented a summarised review of 
the effects following decavanadate in vivo administration on: vanadium accumulation; 
methaemoglobin reductase and Ca2+-pump activities; cardiac, hepatic and renal histology; 
and on overall oxidative stress markers such as: (i) reduced GSH content; (ii) overall rate of 
ROS production; (iii) mitochondrial superoxide anion radical (O2·-) production and (iv) 
lipid peroxidation propagation. 
 
2. STABILITY OF DECAMERIC VANADATE SPECIES 
 
Only a few studies consider the hypothesis of a possible effect of decameric 
vanadate (V10) at physiological conditions since, in these conditions, vanadate (+5 
oxidation state) is considered to be almost totally reduced to vanadyl (+4) and decavanadate 
concentration is very low or is not present for long enough to induce any effects [33-36]. In 
order to correlate the effects observed in vivo with the decameric vanadate species present 
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in solution, it has been determined its stability in the injected solution, estimating the half-
life time of decameric vanadate species on decavanadate solution. 
 
2.1 Decameric species in vanadate solutions: NMR signals  
 
Since most of the vanadate species can be detected by 51V Nuclear Magnetic 
Resonance (RMN) spectroscopy, this technique has been often used to evaluate the 
compositions of vanadate solutions. As appraised by 51V NMR spectroscopy, decavanadate 
stock solution pH 4.0, 50 mM in total vanadium, contains only decameric species since 
only signals from decameric vanadate species are observed: V10A at -515 ppm, V10B at -500 
ppm and V10C at -424 ppm [27]. Conversely to decavanadate stock solution, that contains 
only decameric vanadate species, metavanadate stock solution contains ortho- and 
metavanadate species. However, after dilution in the injection medium containing 0.9% 
NaCl the NMR spectrum of the denominated decavanadate solution (containing presumably 
only decameric species) are also often contaminated with monomeric vanadate species, 
showing besides the decameric NMR signals, a signal at -562 ppm with a half-line 
broadening of 55 Hz (Fig. 2A). In fact, the spectra of decavanadate solution used in 
injections, 5 mM total vanadium in 0.9% NaCl at pH 7.0, contained mainly decameric 
species once the three signals from decameric vanadate species, ascribed to the three 
vanadium atoms of the decavanadate structure are identified [37]. On the other hand, in the 
metavanadate injected solution, 5 mM total vanadium concentration in 0.9% NaCl at pH 
6.98, were detected monomeric (V1), dimeric (V2), tetrameric (V4) and also pentameric (V5) 
species, respectively, at -561 ppm, -575 ppm, -579 ppm and at -587 ppm, as described 
elsewhere [15] (Fig. 2).  
 
 
Figure 2.  105.2 MHz 51V NMR spectra, at room temperature, of decavanadate, (pH 7.0) (A and B) and 
metavanadate (pH 7.0) (C and D) (5 mM total vanadium) in 0.9% NaCl, in the absence (A and C) or in the 
presence (B and D) of 5% blood plasma from S. aurata. All spectra were acquired in the presence of 10% 
D2O. V10A, V10B and V10C are signals of vanadium atoms from the decameric (V10O286-) species. V1 and V2 
NMR signals correspond, respectively, to monomeric (VO43-, HVO42- and H2VO4-) and dimeric (HV2O73- and 
H2V2O72-) vanadate regardless of the protonation state, whereas V4 and V5 correspond to cyclic tetrameric 
(V4O124-) and pentameric (V5O155-) vanadate species, respectively.  
 
Vanadate studies in biological systems can be comparable to the iceberg 
phenomena: there is an invisible part, probably, not most interesting, but certainly the major 
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[24]. For this reason, it is of extreme importance to well characterize the vanadate species 
presence and the interactions with the system in study before attempting to understand the 
promoted effects. Therefore, the NMR studies must be performed in order to certify the 
presence of the vanadate species responsible for a specific effect. For instance, it was 
verified that in the presence of 5% blood plasma in the dilution medium, neither the 
concentration of the different vanadate species nor the ratio between vanadate oligomers in 
both solutions are drastically changed pointing out to vanadate/protein interactions (Table 
1). Moreover, it is possible to deduce specific vanadate/protein interactions by analyzing 
the half-width broadening in the presence of the protein, as it is observed for the decameric 
signals that increase up to 1.5 (V10A), at Table I, in the presence of blood plasma (B). 
Furthermore, after dilution of the decavanadate solution into the injection medium 
(NaCl 0.9%), in the concentrations normally used in the present studies (1 and 5 mM in 
vanadium), the concentration of decameric vanadate increases linearly with total vanadate 
concentration whereas monomeric vanadate does not, as described recently [27, 29]. 
 
2.2. Decavanadate characterization and stability 
 
UV/visible spectroscopic characterization of the injected vanadate solutions showed 
that the decavanadate solution present a characteristic spectrum (Fig. 3A) with visible 
absorbance up to 500 nm due to decameric vanadate species that absorbs at 360 and 400 
nm, while metavanadate solutions spectra almost does not absorb at 400 nm. 
Conversely to metavanadate, the decavanadate solution is unstable in the injection 
medium (NaCl 0.9%) as analysed by UV/visible spectroscopy [26]. In contrast to the labile 
oxovanadates present in the metavanadate solutions, which interconvert on the time scale of 
milliseconds to seconds, decameric vanadate has very slow decomposition kinetics upon 
dilution. Decameric vanadate present in decavanadate solutions decomposes into 
monomeric vanadate species (V1) which solutions are colourless. The kinetics of 
decomposition of decameric species followed by UV/visible spectroscopy, at 25 ºC, in the 
saline solution used for in vivo administration, assessed by measurements of the absorption 
at 400 nm has confirmed a first-order kinetic process, with an half-time of 16 hours 
(measured with 1 mM total vanadate concentration, i.e. 100 µM decameric vanadate 
species) (Fig. 3B). 
After this time, the NMR spectra contain not only decameric vanadate species but 
also the others species present in metavanadate solutions, in agreement to described 
elsewhere [15, 19, 24]. Therefore, this complex oxoanion remains relatively stable at room 
temperature, allowing studying its effects not only in vitro but also in vivo. Moreover, 
decameric vanadate is stabilized upon interaction with cytoskeletal and membrane-bound 
proteins [29]. 
At pH 7, decameric vanadate might not be present in solution depending on several 
parameters such as vanadium concentration, ionic strength or temperature [14]. However, 
once formed at pH 4 and upon the pH adjusted to a physiological value, it decomposes very 
slowly with a half-time that can reach up to 16 hours [21, 23, 27-28, 38]. This is an 
important feature, since decavanadate maintains its structure in an aqueous solution for a 
significant amount of time, allowing it to induce toxic effects in biological systems 
different from the ones promoted by vanadate itself.  
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Table 1.  51V NMR spectral parameters, at room temperature, of the vanadate species 
present in decavanadate (pH 7.0) (A and B) and metavanadate (pH 7.0) (C and D) (5 mM 
total vanadium) in 0.9% NaCl, in the absence (A and C) or in the presence (B and D) of 5% 
fish blood plasma, namely chemical shift (δ), half line width (∆ν½) and concentration of the 
respective vanadate oligomeric species (C). The broadening factor of half line width (F) is 
defined as the coefficient between ∆ν½ value in the absence and presence of 5% plasma. 
The concentration (C) of the vanadate species present in decavanadate and metavanadate 
solutions was determined from the fractions of the integrated areas observed in the 
corresponding spectrum (see Soares et al. [27]). 
 
 
 V1 V2 V4 V5 V10A V10B V10C 
(A) δ (ppm) -561.7 - - - -516.6 -500.8 -425.6 
 ∆ν1/2  (Hz) 55 - - - 206 318 393 
 C (µM) 126 - - - 214 195 79 
(B) δ (ppm) -561.1 - - - -516.1 -500.0 -423.5 
 ∆ν1/2  (Hz) 55 - - - 318 581 807 
 C (µM) 181 - - - 213 189 81 
 
F (relative to A) (1.0) - - - (1.5) (1.8) (2.1) 
(C) δ (ppm) -561.2 -574.5 -578.8 -587.2 - - - 
 ∆ν1/2  (Hz) 93 130 55 130 - - - 
 C (µM) 443 389 903 33 - - - 
(D) δ (ppm) -560.8 -574.4 -578.8 -587.4 - - - 
 ∆ν1/2  (Hz) 93 130 55 93 - - - 
 C (µM) 878 332 865 nd - - - 
 
F (relative to C) (1.0) (1.0) (1.0) (0.7) - - - 
∆ν½ values have a STD of ±20 Hz; nd: not determined. 
 
 
 
 
Figure 3. UV/visible spectra (A), at 25 ºC, of decavanadate (solid) and metavanadate (dash) (1 mM total 
vanadium) solutions, in the injection dilution medium containing 0.9% NaCl, pH 8.0 and variation of the 
absorbance (B) of decavanadate solution (1 mM total vanadium) in 0.9% NaCl, at 400 nm, in function of time 
(adapted from Soares et al. [28]). 
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3. VANADIUM SUBCELLULAR DISTRIBUTION FOLLOWING 
DECAVANADATE ADMINISTRATION  
 
The uptake of vanadium depends on the animal species and age, with the larger 
quantities of vanadium being found in bones, kidney, liver, spleen, plasma, muscle and fat, 
whereas the smallest amounts can be found in brain and other organs [39-41]. Toxicity 
studies with vanadium often disregard the contribution of vanadate oligomers, although 
recent studies demonstrated that the amount of vanadium found in blood plasma, red blood 
cells (RBC) and cardiac muscle subcellular fractions, after an in vivo acute exposure to 
sublethal vanadate concentrations, is affected upon decameric vanadate administration [21, 
24-27]. Nevertheless in acute exposure experiments (from 1 hour to 7 days) following 
exposures to sublethal concentrations of both decavanadate or metavanadate (1 and 5 mM 
total vanadium), it is found that independently of the form of vanadium administrated it can 
penetrate into internal organs of the fish H. didactylus and S. aurata with the following 
order of concentration: blood > heart > liver > kidney > muscle [21, 25-27, 42-43]. 
 
3.1. Blood and Heart 
 
Following an acute exposure of two vanadate solutions – decavanadate and 
metavanadate – containing different vanadate oligomers, different patterns of vanadium 
subcellular distribution in fish blood plasma, red blood cells (RBC) and cardiac muscle 
subcellular fractions was described.  
Indeed, upon an intravenous (i.v.) injection of 1 or 5 mM vanadate (total vanadium) 
in S. aurata, the highest amount of vanadium is found in blood plasma 1 hour after 
administration of both decavanadate and metavanadate solutions, being 80- to 1,000-fold 
higher than in RBC, respectively, if 5 or 1 mM total vanadium is administrated [26-27]. 
Regarding cardiac mitochondria and cytosol, lower amounts of vanadium are found upon 1 
mM vanadate (total vanadium) in vivo administration, not changing with exposure time in 
cytosol (about 50 ng/g dry tissue) for both solutions, while in mitochondria the amount of 
vanadium after the first hour (about 45 ng/g dry tissue) is about half of the vanadium 
content at 6 and 12 hours, for both solutions [27]. Apparently, 1 mM decavanadate does not 
affect vanadium distribution at the earlier times since similar values were observed for 
metavanadate. Previous works done with higher vanadate concentration (5 mM) with the 
same fish species and exposure time show a tendency to vanadium accumulation in 
mitochondria upon decavanadate i.v. administration in comparison to cytosol, being 
accumulated 2-fold higher in cardiac mitochondria [26] (Fig. 4). 
The amount of vanadium in cardiac mitochondria was higher than in cytosol, earlier 
for metavanadate (6 hours) than for decavanadate (12 hours). After 12 hours of 
administration, the amount of vanadium in plasma, as well as in cardiac cytosol, decrease 
about 50% for both vanadate solutions, whereas it remains almost unchanged in 
mitochondria [26] (Fig. 4). In fact, it has been described that the binding of vanadium to 
plasma proteins is of special interest, as the vanadium binding proteins can play a role in 
the transport of vanadium in blood. Transferrin and albumin have been reported to be 
binding proteins for vanadium in human plasma [14]. Besides mitochondria, it has been 
suggested that, at a subcellular level, the majority of vanadium is found in the nucleus [41, 
44-45]. When decavanadate is administered a different fate of intracellular vanadium 
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accumulation was observed in blood plasma and RBC, being vanadium mainly distributed 
in plasma, before accumulated into the mitochondrial fraction [26]. 
 
 
Figure 4. Vanadium concentration on red blood cells (RBC), blood plasma and cardiac mitochondria and 
cytosol of Sparus aurata individuals (n = 4) intravenously injected with 5 mM (total vanadium) decavanadate 
or metavanadate, 1 and 12 hours after exposure (adapted from Soares et al. [26]). 
 
On contrary, for the same concentration (5 mM) and different mode of 
administration (intraperitoneal, i.p.), it was not observed the tendency of vanadium to 
accumulate in cardiac mitochondria upon decavanadate i.p. administration in H. didactylus 
[21].  
In conclusion, in fish cardiac muscle, the vanadium distribution is dependent on the 
administration of decameric vanadate, with vanadium being mainly distributed in plasma, 
before being accumulated into the mitochondria. 
 
3.2. Liver 
 
In hepatic tissue, it has also been described that vanadium accumulation is favoured 
in mitochondria (2-fold higher than in cytosol), 24 hours upon 5 mM decavanadate (total 
vanadium) i.v. injection in H. didactylus [25] (Fig. 5). Moreover, decavanadate solution 
promotes a 5-fold increase (0.135 µg V/g dry tissue, p <0.05) in the vanadium content of 
the mitochondrial fraction 7 days after exposure, whereas no effects were observed after 
metavanadate solution administration [25] (Fig. 5). The general tendency is that both liver 
and cardiac mitochondria may be a vanadium intracellular target. Apparently, for both 
tissues, the vanadium accumulation in mitochondria is favoured upon decavanadate 
administration. 
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 As decavanadate is eventually less permeant through the anionic channel than the 
other vanadate oligomers (due to its molecular size) and likely to be bound with high 
affinity to proteins, therefore preventing its disintegration to vanadate oligomers and 
reduction to vanadyl, it has been suggested that the accumulation of vanadium in liver after 
decavanadate administration is a consequence of a higher level of exposure of liver to total 
vanadium. It is known that decavanadate binds with high affinity with proteins [18-20].  
 
 
Figure 5. Vanadium amounts (µg V/g dry tissue) in mitochondrial (A) and cytosolic (B) subcellular fractions 
of hepatic tissue from Halobatrachus didactylus individuals (n = 5) intravenously injected with 5 mM (total 
vanadium) decavanadate or metavanadate, 1 and 7 days after exposure (mean ± STD); *significantly different 
from control, p <0.05 (adapted from Gândara et al. [25]). 
 
Furthermore, resembling heart tissue, vanadium accumulation in liver is dependent 
on the way of administration. The subcellular distribution of vanadium in liver appears to 
be different than in heart, since mitochondrial and cytosolic fractions of hepatic tissue 
accumulate 10% of total vanadium, while in cardiac tissue the same fractions accumulate 
20% [21, 26-27].  
 
3.3. Kidney 
 
Also in renal tissue, mitochondria present more vanadium than cytosol, indicating 
that mitochondria were the main subcellular target. In a short-term exposure study [43], in 
renal mitochondria from H. didactylus intraperitoneally injected with 5 mM (total 
vanadium) decavanadate, vanadium concentration increased (p <0.05) by 424% 1 day post-
exposure, whereas a 98% increase was reported in metavanadate-treated fish. This 
experiment reveals that, even 7 days upon vanadate administration high amounts of 
vanadium were detected in the kidney of both decavanadate- and metavanadate-treated fish 
(+153% and +231% following decavanadate or metavanadate administration, respectively). 
Conversely, in kidney cytosol, metal concentration increased only upon 1 day of exposure, 
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being vanadate more abundant in cytosolic fraction after decavanadate exposure (+336%) 
than after treatment with metavanadate (+251%), while it were not observed a significant 
increase (p >0.05) 7 days post-treatment. In conclusion, after decavanadate exposure 
vanadium tends to accumulate in subcellular compartments, such as mitochondria [43]. 
 
Figure 6. Vanadium concentration (µg V/g dry tissue) in renal mitochondria (A) and cytosol (B) from 
Halobatrachus didactylus (n = 5) intraperitoneously injected with 5 mM (total vanadium) decavanadate or 
metavanadate, 1 and 7 days after exposure (adapted from Soares et al. [43]). 
 
3.4. Muscle 
 
 Skeletal muscle is one of the tissues with the lowest vanadium accumulation 
described [45]. However, Sousa [42] reported that in S. aurata specimens, intravenously 
injected with 5 mM (total vanadium) decavanadate, the highest percentage of vanadium 
was found in muscle 1 hour after exposition (+96% relatively to control fish; 126 ± 12 ng/g 
dry tissue; p <0.05), whereas the maximum amount of vanadium detected in skeletal 
muscle following metavanadate administration was acquired 12 hours after treatment 
(+94% relatively to non-treated fish; 135 ± 27 ng/g dry tissue; p <0.05) (Fig. 7), suggesting 
that in this tissue decameric vanadate may be accumulated prior than other vanadates. A 
study with H. didactylus intraperitoneally injected with the same amount of vanadate, also 
revealed that the highest amount of vanadium in muscle is detected 24 hours upon exposure 
to decavanadate (+186% relatively to control).  
Besides vanadium is more rapidly accumulated in muscle when administered in the 
form of decavanadate, nevertheless, conversely to observed in vanadium-target organs, in 
fish skeletal muscle it is not observed a preferential accumulation of vanadium upon the 
administration of a specific vanadate oligomeric species, being the accumulation of 
vanadium, administered as decavanadate or metavanadate, very similar (p >0.05). 
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Figure 7. Variation of vanadium amount (%) relatively to control (non-treated fish) in Sparus aurata skeletal 
muscle (n = 4) intravenously injected with 5 mM (total vanadium) decavanadate or metavanadate, 1, 6 and 12 
hours after exposure (adapted from Sousa [42]). 
 
4. DECAVANADATE TOXICITY 
 
Several haematological changes, compromising oxygen transport efficacy, namely 
cell destruction, haemolytic anemia and methaemoglobinemia – oxyhaemoglobin oxidation 
to methaemoglobin – have been described upon vanadium intoxication [5-7, 31, 46-53]. 
Moreover, in vanadium intoxication, besides the increase of red blood cells (RBC) 
breakdown, an increase on methaemoglobin levels has been reported [48, 54-56]. In the 
human erythrocyte, under normal conditions, a small proportion (about 1%) of 
haemoglobin exists as methaemoglobin [57-58]. On contrary, in fish species, haemoglobin 
in the form of methaemoglobin is ten fold greater than in humans [59]. Therefore, studies 
of toxic metals-induced methaemoglobinemia in piscine models are of extreme relevance. 
Cardiovascular effects of heavy metals such as vanadium are also known, namely 
alterations of heart rate, cardiac inotropism and peripheral vascular resistance [60-61], 
although histopathological effects in cardiac tissue are not completely understood. There is 
a strict relationship between cardiac tissue morphology integrity and the maintenance of 
heart functional efficiency [62]. Therefore, characterization of the myocardial tissue may be 
important in evaluating the degree of cellular damage caused by exposure to toxic agents. 
To analysed V10 contribution to vanadate toxicity in haematological and cardiovascular 
systems, following an acute exposure to decavanadate solution, V10-induced changes in 
methaemoglobin reductase and Ca2+-pump activities were determined in intraperitoneally 
injected fish.  
 
4.1. Methaemoglobin reductase activity 
 
Following a short-term exposure (7 days), methaemoglobin reductase activity is 
affected differently after the in vivo administration of decavanadate or metavanadate 
solutions, metavanadate induced an increased of enzymatic activity by 67% (p <0.05), 
while in the presence of decavanadate no significant changes were observed (Fig. 8) [23]. 
Soares and colleagues [23] injected intraperitoneally two vanadate 5 mM (total vanadium) 
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solutions, as decavanadate and metavanadate, in H. didactylus, in order to evaluate the 
effects of oligomeric vanadate species on methaemoglobin reductase activity from fish red 
blood cells (RBC). Although in vivo decameric vanadate did not induces changes in the 
methaemoglobin reductase activity, in vitro studies indicated that decavanadate besides 
strongly decreases methaemoglobin reductase activity (IC50  
50 µM), also interact with haemoglobin, promoting haemoglobin oxidation to 
methaemoglobin, in concentrations as low as 50 µM [23], suggesting that decameric 
vanadate is important to evaluate in vivo and in vitro vanadate effects on methaemoglobin 
reductase activity.  
 
4.2. Decavanadate effects on the activity of sarcoplasmic reticulum Ca2+-pump 
 
Interaction of species present in vanadate solutions with ionic pumps has been 
described [15-16, 63]. In these studies, it is shown that, in non damage native vesicles 
decameric vanadate clearly differs from other oligomeric species in inhibiting Ca2+ uptake 
by sarcoplasmic reticulum (SR) coupled to ATP hydrolysis, Ca2+ efflux coupled with 
ATPase reversed activity (ATP synthesis) and H+ ejection promoted by the SR ATPase 
[15-16, 19]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Halobatrachus didactylus methaemoglobin reductase activity (µmol NAD+/min/g Hb) 1 and 7 days 
after 5 mM (total vanadium) decavanadate or metavanadate in vivo administration (n = 4); *significantly 
different from control, p <0.05 (adapted from Soares et al. [23]). 
 
In vivo measurements of SR calcium pump activity in H. didactylus skeletal muscle 
(70.4 ± 6.65 nmol Pi/min/mg SRV) reflect that ATP hydrolysis by Ca2+-ATPase is 
significantly increased (+52%; p <0.05) 48 hours upon in vivo administration of 5 mM 
(total vanadium) decavanadate, whereas only metavanadate solution decreased it by -15 % 
(p <0.05) 24 hours post-injection (Fig. 9); conversely, to the observed in vitro [64], where 
only decavanadate inhibits the calcium pump (coupled uptake). Therefore, decavanadate 
exert noticeable effects on physiological calcium homeostasis, in particular when coupled 
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with ATP synthesis [64], having reactivity clearly different from the one observed for 
vanadate. 
Different responses obtained on in vivo and in vitro studies prove than in vivo 
metabolism is very complex and great care must be taken on extrapolation from in vitro 
conditions. Biochemical aspects related with decavanadate effects on SR calcium pump 
structure and function are being reviewed in Chapter 7 of this book. 
 
4.3. Histological changes on heart, liver and kidney 
 
Borges and colleagues [22] analysed the contribution of vanadate oligomers to in 
vivo acute histological effects of vanadium in the heart, liver and kidney of H. didactylus 
intraperitoneally injected with a sublethal vanadium dose (5 mM total vanadium, 1 mg/kg) 
in the form of decavanadate or metavanadate. One and seven days post injection, stained 
sections of heart ventricle, renal and hepatic tissue reveal vanadium-induced tissue injuries. 
Both vanadate solutions produced similar effects in the renal tissue. Morphological 
alterations included damaged renal tubules showing disorganized epithelial cells in 
different states of necrosis. Reabsorbed renal tubules and hyperchromatic interstitial tissue 
were also observed. The hepatic tissue presented hyperchromatic and hypertrophied nuclei, 
along with necrosis and hypertrophied hepatocytes, with more severe changes observed 
upon exposure to decavanadate. Vanadate oligomers promoted evident tissue lesions in the 
kidney and liver, but not in the heart. However, cardiac tissue structural changes were 
produced. For instance, decavanadate induces a hypertrophy of the ventricle due to a 
decrease in the percentage of myocardium occupied by collagen fibres [22].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Sarcoplasmic reticulum vesicles (SRV) Ca2+-ATPase activity (nmol Pi/min/mg SRV) from 
Halobatrachus didactylus skeletal muscle (n = 3), at 25 ºC, in a reaction medium containing 0.1 M KCl, 25 
mM HEPES (pH 7.0), 5 mM MgCl2, 50 µM CaCl2 and 0.285 mg protein/ml (mean ± STD); *significantly 
different from control, p <0.05. 
 
Vanadate treatment (either decavanadate or metavanadate) has no effect on the 
fractional area of the subepicardial and subendocardial cardiac tissues that was occupied by 
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various tissues components and no evidence of tissue lesions was found in any of the tissue 
layers. However, vanadate treatment induces changes on the fractional area of myocardium 
that consisted of the different cardiac tissue components (collagen type I, collagen type III, 
muscle tissue and lacunae). Exposure to decavanadate significantly decreased (p <0.05) 
area fractions of collagen I (-69%, one day after vanadium exposure) and collagen III (-
37% and -42%, 1 and 7 days after exposure, respectively) (Fig. 10). In contrast, the area 
occupied by muscle cells increased significantly (p <0.05) by +11% and +8%, 1 and 7 days 
upon exposure, respectively. Furthermore, the exposure to metavanadate also decrease (p 
<0.05) the percentage of myocardial area occupied by collagen I (-21%, one day after 
exposure to metavanadate) and collagen III (-18% and -44%, 1 and 7 days following 
vanadate treatment), whereas there was a significant increase (p <0.05) in the area of 
muscle fibres (+13%, one day upon exposure to metavanadate) (Fig. 10).  
Moreover, decavanadate-treated toadfish shows an increased in relative cardiac and 
ventricular masses, in simultaneous – but opposite – with the changes in the fractional 
myocardial area composed of collagen (decrease) and muscle fibres (increase) [22]. 
Further, because these effects are more pronounced upon decavanadate intoxication, versus 
metavanadate-treated fish, it is suggested that the exposure to decameric vanadate species 
might interfere with collagen metabolism and induce ventricular remodelling.  
 
 
Figure 10. Variation of the fractional area (%) of myocardial images which is composed by the various tissue 
components: collagen type I (A), collagen type III (B) and muscle tissue (C) (n = 5); *significantly different 
from control, p <0.05 (adapted from Borges et al. [22]). 
 
5. LIPID PEROXIDATION AND OXIDATIVE STRESS MARKERS UPON 
DECAVANADATE in vivo ADMINISTRATION 
 
Intracellularly vanadate (vanadium 5+) is reduced to vanadyl (vanadium 4+) by 
several antioxidant compounds, preventing vanadate toxic effects [9]. Several in vivo 
animal studies associate vanadate with oxidative stress and lipid peroxidation [7]. It was 
recently demonstrated that the acute exposure to decavanadate induce stronger effects than 
metavanadate increasing oxidative stress, by depressing the activity of antioxidant enzymes 
(catalase, superoxide dismutase and glutathione peroxidase) and increasing the lipid 
peroxidation in cardiac, hepatic and renal tissues [21, 24-25, 27, 42-43]. 
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5.1. Glutathione (GSH) content 
 
Reduced glutathione (GSH) is known to be one of the most important intracellular 
anti-oxidants, being considered the largest component of an endogenous cellular “redox 
buffer” [34, 65] and, since GSH was found to be involved in vanadate bioreduction [10-12, 
66-68], it is expected that the levels of GSH should be affected when vanadate is 
administered. Several works has reported that the GSH pool is enhanced in the presence of 
vanadate [69-70]. More recently, Soares and colleagues observed a 135% (p <0.001) 
increased in cardiac GSH levels 24 hours upon 5 mM (total vanadium) decavanadate 
intravenously (i.v.) administration and an enhancement of 171% and 120% 12 and 24 hours 
after metavanadate injection, respectively, in H. didactylus species (Fig. 11). The simplest 
explanation for this is that the decomposition of decavanadate will produce a delayed 
exposure of heart to metavanadate, although no similar observation can be made regarding 
other oxidative stress parameters.  
On the other and, in hepatic tissue the GSH status is differently affected upon 
administration of both decavanadate and metavanadate solutions (5 mM total vanadium) in 
H. didactylus [25]. Whereas basal GSH content (7.8 ± 3.0 nmol/mg protein) did not shows 
significant changes after decavanadate solution i.v. administration, metavanadate solution 
administration increased GSH status up to 20 and 35%, after 12 and 24 hours, respectively. 
Therefore, cardiac muscle is considered to be more sensitive to oligovanadates oxidative 
stress than hepatic tissue. Once more, different organs show different sensitivities to 
decavanadate in comparison to other vanadate oligomers. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Reduced glutathione content (nmol GSH/mg protein) in the cardiac tissue of Halobatrachus 
didactylus (n = 5) intravenously injected with decavanadate or metavanadate (5 mM total vanadium; 1 
mg/kg), 12 and 24 hours post-exposure (mean ± STD); *significantly different from control, p <0.05. 
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5.2. Reactive Oxygen Species (ROS) production 
 
As well as other toxic metals, vanadium is known to exhibit the ability to produce 
ROS, resulting in lipid peroxidation and antioxidant enzyme alterations [9]. Vanadium can 
induce the formation of ROS in biological systems through: (i) Fenton-like reactions [7]; 
(ii) vanadate bioreduction mediated by GSH, flavoenzymes or NAD(P)H oxidases with 
ROS as a by-product [10-12, 66-68]; and (iii) recent evidences point out to and indirect 
promotion of ROS production, probably by interacting with mitochondria redox centres 
[13]. Moreover, vanadium toxicological effects in several cell types have been related with 
ROS production [13, 71-73]. Several suggestions on vanadate relation with ROS were 
made so far; nonetheless more work is needed to clarify whether vanadate speciation in 
vivo, its reduction, its action mechanisms and pathways could have different physiologic 
roles.  
The overall pro-oxidant activity upon in vivo vanadate exposure has been 
determined by quantitative analysis of ROS production and shows that, in fish heart 
mitochondria, only metavanadate induces a significant and delayed increase (p <0.05) in 
ROS production. The basal value for pro-oxidant activity in cardiac tissue 384 ± 140 
a.u./min/mg protein increased above 198% (p <0.05), 12 hours after metavanadate 
administration, whereas no significant effects were observed for decavanadate [27] (Fig. 
12A). In liver tissue, both vanadate oligomers affect differently pro-oxidant activity: 
decavanadate enhances by about 80% the rate of ROS production for the duration of the 
exposure (12 hours), whereas metavanadate induces a 150% increase upon the first hour of 
exposure, being its pro-oxidant ability blocked throughout the 12 hours of exposure (40% 
and almost zero, 6 and 12 hours after vanadium exposure, respectively) (Fig. 12B).  
Therefore, differential effects of decavanadate and metavanadate on ROS 
production should be expected on the light of the previous data. However, another similar 
in vivo study [25] reports an antioxidant action promoted by both vanadates in liver. 
Decavanadate-administered H. didactylus have a weak enhancement of ROS production 12 
hours after exposition (about 15% increase), but 24 hours after ROS production decreased 
nearly 30%. On contrary, metavanadate-administered individuals showed a decrease of up 
to 40% in the overall rate of ROS production (12 and 24 hours), which is consistent with 
the observed increase in GSH content. Once more, the simplest explanation for the fact that 
decameric vanadate mimics the behaviour observed with metavanadate solution is that 
decomposition of decavanadate will produce a delayed exposure of the liver to 
metavanadate. In fact, this effect is also observed regarding the GSH content, described in 
the same conditions for the same organ. 
Even though vanadium may participate in Fenton-like reactions [7], together with 
the proposed mechanisms of vanadate action that involves its bioreduction and ROS 
production [12, 72-74], results point out to a depression in the overall rate of ROS 
production. This observation is in good agreement with previous reports showing that 
vanadate supplementation diminished oxidative stress in certain experimental conditions, 
such as in rat-induced hepatocarcinogenesis [69] and in rat diabetic tissues [75]. Regarding 
superoxide anion radical (O2.-) production in hepatic mitochondrial fraction, once again it 
was observed that metavanadate and decavanadate promoted opposite effects: 12 hours 
after exposition, the rate of O2.- production decreased 35% in decavanadate-administered 
individuals, while  metavanadate administration induced an up to 45% increased in the rate. 
On other hand, 24 hours after the results are reverted, decavanadate promoted a 30% 
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increase, and metavanadate decreased O2.- production in 40%. Thus, decameric vanadate 
species induced changes in O2.- mitochondrial production opposite to those produced by the 
oligomeric vanadate species that are present in metavanadate solution, from which it can be 
suggested again different pathways of biological action for the different oligomers. Several 
proposed vanadate action pathways within cells involves O2.- production mediated by 
NADPH oxido-reductases from the respiratory chain [12, 72-74]. If it is consider the action 
and detoxification mechanism proposed for vanadate, where vanadate is reduced to vanadyl 
with production of O2.-, it is possible that decavanadate participates in such reactions in a 
different manner. Note also that after 24 hours, the increase in O2.- in decavanadate-
administered individuals correlated with the increase of vanadium concentration in the 
mitochondrial fraction. 
 
 
Figure 12. Overall rate of reactive oxygen species (ROS) production variation in cardiac (A) and hepatic (B) 
mitochondria of Sparus aurata (n = 6) intravenously injected with decavanadate or metavanadate (1 mM total 
vanadium; 1 mg/kg); *significantly different from control, p <0.05 (adapted from Soares et al. [27]). 
 
5.3. Antioxidant enzymes activities 
 
Several biological studies associate vanadium with the ability to produce ROS, 
resulting in lipid peroxidation and antioxidant enzymes alterations, leading to oxidative 
stress [7, 9-10, 12, 66, 67-68, 74]. 
In agreement with the increase in ROS production previously reported (see section 
6.2.), 1 mM metavanadate induces an increase (+115%) in mitocondrial superoxide 
dismutase (SOD) activity (p <0.05), 12 hours after exposure, while decavanadate increases 
about 30% (p <0.05) (at 1 and 12 hours after intravenous, i.v., administration) [27] (Table 
2). It is known that SOD activity may increase with the need of protection against oxidant 
agents, such as vanadate. Apparently, only metavanadate act as a pro-oxidant since 
decavanadate does not induce the same overall response probably due to different 
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reactivities that can result from different mechanisms. Concerning mitochondrial catalase 
(CAT) activity, the basal CAT activity in mitochondria (1.63 ± 0.51 nmol/min/mg protein) 
decrease by -55% (p <0.05) 12 hours after decavanadate exposure, whereas metavanadate 
induced no significant effects [27] (Table 2). Putting it all together, 1 mM decavanadate in 
vivo administration differs from metavanadate in not inducing cardiac mitochondrial ROS 
production and SOD activity besides decreasing CAT activity. Therefore, more pronounced 
pro-oxidant effects occur in cardiac mitochondria following i.v. metavanadate exposure 
whereas decavanadate administration seems to prevent this effect, probably by binding to 
target proteins that prevent its decomposition to vanadate that induces the producing of 
ROS or due to different reactivities. In conclusion, once formed decameric vanadate species 
has a different reactivity than vanadate, thus, pointing out that the differential contribution 
of vanadium oligomers should be taken into account to rationalize in vivo vanadate toxicity. 
The decrease on the activity of CAT by decameric vanadate, is in agreement to 
previous results from the same laboratory, which reported that decavanadate induce a 
decrease in cardiac mitochondrial CAT activity (-60%), 7 days following 5 mM 
decavanadate intraperitoneal (i.p.) administration in H. didactylus [21] (Table 2). Cytosolic 
CAT activity decreased (15-20%) for both contaminated groups, upon vanadium exposure. 
However, in the metavanadate-contaminated group, the CAT activity decreased after 1 day 
of exposure (-19%) while the decavanadate group showed the strongest decrease (p <0.05) 
of CAT cytosolic activity, observed after 7 days of decavanadate intoxication (-56%). 
Mitochondrial CAT activity showed less evident variations, with a slight increase after 1 
and 7 days of metavanadate exposition and a minor decrease during the same period upon 
decavanadate exposure. The same group reported a SOD activity decrease, in cytosol, after 
vanadium intoxication, for both groups, with a strongest inhibition observed in 
decavanadate-treated group, 7 days after of exposure. For the mitochondrial SOD activity, 
also no significant responses were observed, although the decavanadate-treated group 
showed an increase of 23% after 1 days of exposure. GPx activity was not significant 
affected by vanadate. However, metavanadate induced a decreased in total-GPx, after 7 
days of exposure (-35%), whereas the decrease observed in the decavanadate-treated group, 
observed upon 1 day (-20%), fades out 7 days after exposition. Conversely, both vanadate 
solutions intoxication decreased the Se-GPx activity, being the effects depressed or 
stimulated upon 1 or 7 days of metavanadate or decavanadate exposition, respectively. The 
activities of cytosolic SOD and CAT, exposed to 1 mg/kg of vanadium, registered a 
decrease immediately after 24 hours of exposure, suggesting an early cellular response to 
vanadium intoxication for both vanadate solutions. 
Reduction of CAT activity was also described in fish exposure to cadmium [76] and 
silver [77]. On the other hand, a previous study [21] concluded that there are not any 
significant changes in mitochondrial SOD activity in H. didactylus, 1 and 7 days following 
i.p. exposure to 5 mM decavanadate or metavanadate (Table 2). In heart, more pronounced 
pro-oxidant effects occur in cardiac mitochondria following i.v. metavanadate exposure 
whereas decavanadate administration seems to prevent this effect. In hepatic tissue, it was 
described that decavanadate and metavanadate administration clearly induce different 
changes in oxidative stress markers [25]. Therefore, the antioxidants responses induced by 
vanadate may depend on the total vanadium concentration administered, on the way of 
exposure and/or vary between fish species, besides the vanadate species composition of 
vanadate solutions. 
 
 20 
 
 
Table 2. Decavanadate and metavanadate effects (, enhancement; , decrease) on cardiac 
mitochondria antioxidant enzymes activities (SOD, superoxide dismutase: CAT, catalase; 
total GPx, total glutathione peroxidases; Se-GPx, selenium-dependent glutathione 
peroxidases) from Halobatrachus didactylus and Sparus aurata injected with two different 
vanadate doses (1 and 5 mM total vanadium). 
 
Organ Vanadate Enzyme Effect Author 
Halobatrachus didactylus (5 mM total vanadium intraperitoneally injected) 
Heart Decavanadate SOD       +23% 
 
 CAT 
      -60% 
 
 Total GPx 
      -20% 
 
 Se-GPx 
      -14% 
Aureliano et al. [21] 
 
Metavanadate SOD = 
 
 CAT = 
 
 Total GPx 
      -35% 
 
 Se-GPx 
      -18% 
Aureliano et al. [21] 
Sparus aurata (1 mM total vanadium intravenously injected) 
Heart Decavanadate SOD       +30% 
 
 CAT 
      -55% Soares et al. [27] 
 
Metavanadate SOD 
      +115% 
 
 CAT = Soares et al. [27] 
 
 
5.4. Lipid peroxidation 
 
Lipid peroxidation is commonly observed following enhanced ROS production in 
the cellular medium. Without specifying which vanadate species were present, it has been 
shown that vanadate can attenuate hepatic lipid peroxidation in induced 
hepatocarcinogenesis [69] and in 7,12-dimethylbenz(a)anthracene (DMBA) induced 
mammary carcinogenesis [78] and that vanadate does not change lipid peroxidation of 
control subjects [78]. 
 Earlier cellular responses induced by decameric vanadate are currently being carried 
out looking for shorten times of exposition such as 1, 2 and 6 hours. However, it was 
observed that 1 hour upon intravenous (i.v.) administration both decavanadate and 
metavanadate (1 mM total vanadium) increase cardiac tissue lipid peroxidation in the same 
extent (about 20%) [27]. Obviously, for higher vanadate concentration (5 mM total 
vanadium), but different mode of administration (intraperitoneal, i.p.) – longer exposure 
times, different fish species (H. didactylus), but for the same tissue – it was described a 
significant increase (p <0.05) in cardiac tissue lipid peroxidation propagation only 7 days 
after i.p. administration in H. didactylus (about 80% and 60% upon decavanadate and 
metavanadate, respectively) [21]. Recently, it was demonstrated that for higher vanadate 
concentration (5 mM), different longer exposure times, but for the same tissue (heart) and 
fish specie of H. didactylus, a significant increase (p <0.05) in cardiac tissue lipid 
peroxidation propagation was observed after 1 and 7 days after decavanadate exposure 
whereas no effects where observed for metavanadate (Fig. 13) [64].  
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Figure 13. Lipid peroxidation propagation variation in Halobatrachus didactylus heart, 1 and 7 days 
following decavanadate and metavanadate (5 mM total vanadate) in vivo administration. Variation is 
calculated based on basal values. Values are present as means ± SD (n = 6); *significantly different from 
control, p <0.05 (adapted from Aureliano et al. [64]). 
 
In fish liver tissue (H. didactylus) a 80% increase (p <0.05) in lipid peroxidation 
was observed 24 hours after intravenous (i.v.) administration of both decavanadate or 
metavanadate solutions (5 mM total vanadium) [25]. In that study, decameric vanadate does 
not promotes significant changes 12 hours after administration, in agreement to recently 
obtained in S. aurata individuals, i.v. injected with 1 mM total vanadium, where 
metavanadate increased lipid peroxidation products by about 55% (p <0.05). As previously 
referred elsewhere [21, 79], decavanadate intoxication did not induce changes in the rate of 
lipid peroxidation till 12 hours, but later increased 80%, which is similar to the increase 
observed in metavanadate-administered individuals after 24 hours. Therefore, for higher (5 
mM) decavanadate concentrations a delayed time effect in lipid peroxidation is observed 
for decavanadate in comparison to metavanadate, probably due to its stability at 
physiological pH.  
For lower concentrations of vanadate (1 mM) both solutions induced lipid 
peroxidation, but once again the effects reveal to be different and dependent on the time 
after administration. It is suggested that decameric vanadate species induce peroxidation 
due to a different reactivity or even prevent the effects promoted by metavanadate since it 
does not maintain the levels exhibited by metavanadate, 6 and 12 hours after exposure. 
Eventually, after administration, the total decomposition of decameric species into 
metavanadate would not induce the same effects observed for the latter solution. Probably, 
the interactions promoted by the labile oxovanadates are different from the ones induced by 
decameric vanadate. Moreover, by the time that decavanadate would totally decompose 
into other vanadate oligomers the targets may not be the same in order to induce the same 
effects as before.  
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Clearly, the decameric species are the promoters of lipid peroxidation since 
metavanadate solution, that also contains monomeric species, has a lower effect. This 
peroxidative injury seems to be related to the reduction of the antioxidant enzyme activity. 
 
6. MITOCHONDRIA AS A TARGET FOR DECAVANADATE TOXICITY 
 
Mitochondria tend to be concentrated in tissues in which the energy demand is high. 
Thus, a compound that inhibits mitochondrial oxidative phosphorylation can therefore have 
a profound effect on the metabolism of important organs like the heart, kidney, liver and 
brain. Several reports have pointed out that mitochondria are one of the target organelles 
for vanadium [33, 80]. In fact, vanadium subcellular distribution results (see section 4) 
showed that the mitochondrial fraction tends to accumulate more vanadium after 
decavanadate solution administration [26-27] than upon vanadate exposure. Moreover, 
decavanadate in vivo administration points out to specific effects in mitochondrial activity 
[28] besides affecting mitochondrial antioxidants enzyme activities [21, 25, 27]. These 
results suggested that decavanadate is not behaving in the same way as other vanadate 
oligomers and indicated that, apparently, the mitochondria seem to be a target for 
decavanadate. All the above data support the hypothesis that mitochondria is might be a 
target for decameric vanadate species. This hypothesis has been further explored and recent 
evidences [28, 81] report that decameric vanadate inhibits mitochondrial respiration and 
induces mitochondrial membrane depolarization in vitro in a larger extent that 
metavanadate, in both rat liver and fish heart mitochondria [28, 64, 81]. For instance, 
decavanadate concentration as low as 0.5 µM, inhibits by about 50% oxygen consumption 
in intact cardiac mitochondria, while a 50-fold higher concentration of metavanadate (25 
µM) is needed to induce the same effect (Fig. 14A) pointing out mitochondria as a potential 
cellular target for decavanadate toxicity [81]. Moreover, decameric vanadate also induced 
cardiac mitochondrial depolarization (IC50 0.5 µM) strongly than metavanadate (IC50 50 
µM) (Fig. 14B) [81]. In intact mitochondria both oxygen consumption and membrane 
potential decreases with increasing concentrations of both vanadate solutions. 
Decavanadate inhibits both mitochondrial oxygen consumption and membrane 
potential strongly than vanadate, acting as a potent respiratory chain inhibitor probably by 
affecting complex III [28]. 
 
7. CONCLUDING REMARKS 
 
Although decameric vanadate is not frequently taken into consideration to account 
for the effect of vanadium in most biological studies, it is to be noted that due to its unusual 
long stability at physiological pH, it may not completely decompose into monomeric 
vanadate before inducing changes in several cellular stress markers, thus allowing to study 
its effects not only in vitro but also in vivo. Recent studies about the contribution of 
decameric vanadate to vanadate toxicity are useful to gain a deeper knowledge in vanadium 
biochemical effects. Moreover, piscine models seem to be adequate to study the effects of 
the administration of decavanadate in antioxidant stress markers, lipid peroxidation and 
vanadium subcellular distribution, not only due to the physiological temperature but also 
due to their sensitivity the metal toxicity. 
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Figure 14.  Decavanadate (solid circles) and metavanadate (open circles) in vitro inhibitory effect (up to 25 
µM total vanadium) on fish heart mitochondrial (2 mg protein/ml) oxygen consumption (%), measured with 
an oxygen electrode (A); and, mitochondrial membrane depolarization (%) by decavanadate (solid triangles) 
and metavanadate (open triangles) on fish cardiac mitochondria (15 µg protein/ml), at 25 ºC, in the presence 
of 5 mM GSH (B); mean ± STD (adapted from Soares et al. [81]). 
 
Decameric vanadate promotes tissue lesions in liver and kidney, but not in the heart. 
However, cardiac muscle structural changes were produced, like a ventricular hypertrophy 
due to a decrease in the percentage of myocardial collagen fibres occupancy. However, the 
in vivo mechanisms involved in the described morphological alterations need to be further 
explored. 
Vanadium subcellular distribution in cardiac, hepatic and renal mitochondria is 
dependent on total vanadium concentration and mode of administration. Moreover, 
mitochondria seem to be an intracellular target for vanadium accumulation following 
decameric vanadate in vivo administration. In fact, major alterations in mitochondrial 
antioxidant enzymes have been described upon exposure to decameric vanadate. Recent 
evidences reveal mitochondria as a target for decameric vanadate, reporting that decameric 
vanadate species inhibits mitochondrial respiration and induces mitochondrial membrane 
depolarization in a larger extent than vanadate, in both hepatic and cardiac mitochondria.  
These results point out to the importance of taking into account decameric vanadate 
in the evaluation of vanadium biological effects. It is believed that the progress in 
understanding the role and the contribution of decavanadate to vanadium biological effects 
may be useful to gain a deeper knowledge in vanadium biochemistry. Therefore, based on 
the results of our experiments, in the present study it is proposed that decameric vanadate 
exhibits pro-oxidant activity through the promotion of superoxide anion formation (O2.-); 
this burst is followed by a concomitant increase in superoxide dismutase (SOD) activity; 
the hydrogen peroxide (H2O2) thus produces will enhances the activity of glutathione 
peroxidases; leading to a raise in reduced glutathione (GSH) content; whereas O2.-, by its 
turn, will induce lipid peroxidation through Haber-Weiss reaction (Fig. 15). It seems that 
the oxidant decavanadate activity does not follow through the direct induction of H2O2 
production, as well as catalase antioxidant activity may not be related to the oxidative stress 
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responses against decameric vanadate toxic effects; thus, the observed peroxidation of lipid 
membranes upon in vivo administration of decavanadate is likely to be not linked to 
stimulation of Fenton reactions (Fig. 15). However, several questions remain to be address, 
such as: (i) Which are the subcellular and molecular targets of decavanadate with 
physiological relevance? (ii) Is decavanadate-induced oxidative stress due to its 
decomposition?  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. Summary of the proposed decavanadate pathways for the generation of reactive oxygen species 
and of the actions in some of the enzymes involved in antioxidant defences in cells (adapted from Storey 
[65]). 
 
Putting it all together, it is proposed that once formed decameric vanadate species 
clearly induce differential biological responses than labile oxovanadates, probably due to 
different reactivities that can result from different mechanisms, thus pointing out the 
importance of taking in account the decavanadate contribution to the evaluation and 
rationalization of in vivo vanadate toxicity effects.  
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